全球体内CRO市场规模、份额、趋势和成长分析报告（2026-2034年）

预计体内 CRO 市场将从 2025 年的 54 亿美元成长到 2034 年的 117.1 亿美元，2026 年至 2034 年的复合年增长率为 8.97%。

随着製药和生物技术公司越来越多地将临床前研究活动外包，全球体内CRO市场正经历强劲成长。体内CRO进行动物实验，以评估新药在临床试验前的安全性和有效性。外包这些研究使公司能够利用专业知识、先进的实验室设施和法规遵循支援。

随着药物研发计画的增加和生物疗法的日益复杂，对体内研究服务的需求也日益增长。合约研究组织（CRO）提供广泛的服务，包括毒性测试、药物动力学研究和疾病模型建构。製药公司依靠这些服务来缩短研发週期，同时维持高标准的研究品质。此外，成像技术和生物标记分析的进步也提高了体内研究的品质。

随着全球药物研发管线的不断扩展，市场预计将持续成长。对生物技术研究和个人化医疗投入的增加将为合约研究组织（CRO）服务提供者创造新的机会。随着药物研发日益复杂，监管要求也日益严格，专业体内研究机构的角色将变得更加重要。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球体内CRO市场：依分子类型划分

• 市场分析、洞察与预测
• 低分子化合物
• 大分子

第五章：全球体内CRO市场：依治疗领域划分

• 市场分析、洞察与预测
• 肿瘤学
• 心臟病学
• 糖尿病
• 自体免疫疾病/发炎性疾病
• 感染疾病
• 中枢神经系统疾病
• 其他的

第六章：全球体内CRO市场：依服务类型划分

• 市场分析、洞察与预测
• 临床前试验
• 临床研究服务
• 检查服务
• 咨询服务

第七章：全球体内CRO市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • IQVIA Inc
  • Crown Bioscience Inc
  • Taconic Biosciences Inc
  • PsychoGenics Inc
  • Evotec SE
  • Janvier Labs
  • Biocytogen Co. Ltd
  • GemPharmatech Co. Ltd
  • Charles River Laboratories International
  • ICON Plc
  • Labcorp Drug Development
  • Parexel International Corporation
  • SMO Clinical Research（I）Pvt Ltd
  • WuXi AppTec Co. Ltd
  • Syneos Health

The In Vivo CRO Market size is expected to reach USD 11.71 Billion in 2034 from USD 5.40 Billion (2025) growing at a CAGR of 8.97% during 2026-2034.

The global in vivo CRO market is experiencing strong growth as pharmaceutical and biotechnology companies increasingly outsource preclinical research activities. In vivo contract research organizations conduct animal-based studies to evaluate the safety and efficacy of new drugs before clinical trials. Outsourcing these studies allows companies to access specialized expertise, advanced laboratory facilities, and regulatory compliance support.

The increasing number of drug discovery programs and the growing complexity of biological therapies are driving demand for in vivo research services. CROs provide a wide range of services including toxicology testing, pharmacokinetic studies, and disease model development. Pharmaceutical companies rely on these services to accelerate drug development timelines while maintaining high research standards. Additionally, technological advancements in imaging and biomarker analysis are improving the quality of in vivo research.

Looking forward, the market is expected to expand as the global pharmaceutical pipeline continues to grow. Increasing investment in biotechnology research and personalized medicine will create new opportunities for CRO service providers. As drug development becomes more complex and regulatory requirements become stricter, the role of specialized in vivo research organizations will become even more important.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type of Molecule

• Small Molecules
• Large Molecules

By Therapeutic Area

• Oncology
• Cardiology
• Diabetes
• Autoimmune/Inflammation Conditions
• Infectious Diseases
• CNS Conditions
• Others

By Service Type

• Preclinical Testing
• Clinical Research Services
• Laboratory Services
• Consulting Services

COMPANIES PROFILED

• IQVIA Inc, Crown Bioscience Inc, Taconic Biosciences Inc, PsychoGenics Inc, Evotec SE, Janvier Labs, Biocytogen Co Ltd, GemPharmatech Co Ltd, Charles River Laboratories International, ICON plc, Labcorp Drug Development, Parexel International Corporation, SMO Clinical Research I Pvt Ltd, WuXi AppTec Co Ltd, Syneos Health
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL IN VIVO CRO MARKET: BY TYPE OF MOLECULE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type Of Molecule
• 4.2. Small Molecules Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Large Molecules Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL IN VIVO CRO MARKET: BY THERAPEUTIC AREA 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Therapeutic Area
• 5.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Cardiology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Diabetes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Autoimmune/Inflammation Conditions Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. CNS Conditions Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL IN VIVO CRO MARKET: BY SERVICE TYPE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Service Type
• 6.2. Preclinical Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Clinical Research Services Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Laboratory Services Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Consulting Services Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL IN VIVO CRO MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Type Of Molecule
  • 7.2.2 By Therapeutic Area
  • 7.2.3 By Service Type
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Type Of Molecule
  • 7.3.2 By Therapeutic Area
  • 7.3.3 By Service Type
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Type Of Molecule
  • 7.4.2 By Therapeutic Area
  • 7.4.3 By Service Type
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Type Of Molecule
  • 7.5.2 By Therapeutic Area
  • 7.5.3 By Service Type
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Type Of Molecule
  • 7.6.2 By Therapeutic Area
  • 7.6.3 By Service Type
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL IN VIVO CRO INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 IQVIA Inc
  • 9.2.2 Crown Bioscience Inc
  • 9.2.3 Taconic Biosciences Inc
  • 9.2.4 PsychoGenics Inc
  • 9.2.5 Evotec SE
  • 9.2.6 Janvier Labs
  • 9.2.7 Biocytogen Co. Ltd
  • 9.2.8 GemPharmatech Co. Ltd
  • 9.2.9 Charles River Laboratories International
  • 9.2.10 ICON Plc
  • 9.2.11 Labcorp Drug Development
  • 9.2.12 Parexel International Corporation
  • 9.2.13 SMO Clinical Research (I) Pvt Ltd
  • 9.2.14 WuXi AppTec Co. Ltd
  • 9.2.15 Syneos Health